nearly a year before the first clinical signs of disease progression. In the rest of the cases,
application of more comprehensive mutation screening approaches is warranted to unveil the
alternative underlying reasons for disease progression.
Supporting grants: NKFIH K16-119950, KH17-126718 and NVKP_16-1-2016-0004; ÚNKP-19-3-
I-SE-33, ÚNKP-19-4-SE-77; STIA_18_KF, HAS LP95021; János Bolyai Scholarship Program;
EFOP-3.6.3-VEKOP-16-2017-00009
POSTER 1
